FDA Approves Zyn Nicotine Pouches to Claim Lower Risk Than Cigarettes

The Food and Drug Administration (FDA) has granted Philip Morris International (PMI), the owner of Zyn nicotine pouches, permission to market its products with a modified-risk claim. This approval allows PMI to state that using Zyn instead of cigarettes reduces the risk of developing mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. The decision is based on extensive scientific evidence indicating that nicotine pouches are significantly less harmful than traditional smoking. According to the FDA, switching from cigarettes to nicotine pouches can substantially decrease exposure to numerous dangerous chemicals found in tobacco products.

Research published in 2023 confirmed these findings through a randomized controlled study showing that individuals who switched from cigarettes to Zyn experienced a significant reduction in harmful chemical exposure within just one week of use. The study also noted that those who completely quit smoking saw similar reductions, suggesting that nicotine pouches offer a viable harm-reduction strategy for smokers looking to minimize health risks. Additionally, studies conducted in Saudi Arabia and the United States have shown that nicotine pouches not only reduce cigarette consumption but also help users achieve better overall health outcomes.

These developments underscore the potential of nicotine pouches as an alternative to smoking, particularly among populations where quitting cold turkey is less likely due to socioeconomic factors or addiction severity. The FDA's decision marks a significant step in recognizing and promoting safer tobacco alternatives for public health benefits.